Alecensa 150 MG capsule UU 240S
Ended Awarded Last action
- Contract number
- SPE2DR26FKKM8
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $28,029
Award facts
- Contract value 100% obligated
- $28,028.92 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $28,028.92 to DMS Pharmaceutical Group Inc. for Alecensa 150 mg capsules (240-count units) on January 27, 2026, with an ultimate completion date of February 18, 2026. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was selected without a set-aside designation, demonstrating the company's competitive capability in unrestricted federal procurement. The delivery order will be performed at the vendor's Park Ridge facility and represents a routine pharmaceutical supply requirement under the company's existing contract vehicle.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to support recurring medical supply needs of military healthcare facilities worldwide. The parent IDC, designated SPE2DR and awarded on November 13, 2025, carries a $499.999 billion ceiling value and extends through December 31, 2036, with a 30-month base period and three 30-month option periods. Alecensa is a targeted cancer therapy commonly used in the treatment of non-small cell lung cancer, reflecting DMS Pharmaceutical Group's established capability to supply specialized and branded pharmaceutical products essential to Department of Defense healthcare operations globally.
Quick answers
Who was awarded contract SPE2DR26FKKM8?
SPE2DR26FKKM8 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 27, 2026.
How much is contract SPE2DR26FKKM8 worth?
The government has obligated $28,029 on SPE2DR26FKKM8.
Is contract SPE2DR26FKKM8 an order under another contract?
Yes. SPE2DR26FKKM8 is a delivery order under SPE2DR25D9367, an indefinite delivery contract.
Was contract SPE2DR26FKKM8 competed?
The extent of competition for SPE2DR26FKKM8 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award